The promise of pharmacogenomics is to improve drug safety and efficacy by using an understanding of an individual’s genome to guide treatment decisions. For this model to become a reality, drug-response assays must be available to ordering clinicians in a validated and certified laboratory environment. This objective aims to select relevant genetic tests for implementation, and develop and validate appropriate assays.
Lead PI (HI) : JJ Liu (GIS)
Co-investigators Alexander Lezhava